Research progress of assessment of minimal residual disease in acute myeloid leukemia / 白血病·淋巴瘤

ABSTRACT

Assessment of minimal residual disease (MRD) in acute myeloid leukemia (AML) patients is now possible by using updated methods including real-time quantitative PCR (RQ-PCR) for abnormal fusion transcripts and multiparameter flow cytometry (MFC) for detecting leukemia-associated phenotypes.Using these techniques,MRD analysis has shown value in terms of risk assessment,continued patient monitoring,and therapeutic decision-making.